Instil Bio, Inc. (TIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
TIL Stock Price Chart Interactive Chart >
TIL Price/Volume Stats
| Current price | $6.00 | 52-week high | $23.68 |
| Prev. close | $7.93 | 52-week low | $4.34 |
| Day low | $4.34 | Volume | 5,801,200 |
| Day high | $7.88 | Avg. volume | 430,996 |
| 50-day MA | $8.70 | Dividend yield | N/A |
| 200-day MA | $14.68 | Market Cap | 775.76M |
Instil Bio, Inc. (TIL) Company Bio
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Latest TIL News From Around the Web
Below are the latest news stories about Instil Bio Inc that investors may wish to consider to help them evaluate TIL as an investment opportunity.
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatePatients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1)Fast Track Designation granted by FDA for ITIL-168 in metastatic melanomaCoStAR mechanism of action data presented at SITC 2021Successful pre-IND meeting for ITIL-306 DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cance |
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual MeetingDALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations demonstrating pre-clinical data of the CoStimulatory Antigen Receptor (CoStAR) platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021), held from November 10-14, 2021. Instil also presen |
Was The Smart Money Right About Instil Bio, Inc. (TIL)?In this article we are going to use hedge fund sentiment as a tool and determine whether Instil Bio, Inc. (NASDAQ:TIL) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, […] |
Instil Bio to Present at Upcoming Investor Conferences in NovemberDALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in November: Cowen 5th Annual IO Next SummitMonday, November 15, 2021Session Time: 4:45 PM – 5:05 PM ETLive Session Link: https://wsw.com/admin/link/presenter.aspx? |
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO CongressDALLAS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced today that a subset analysis of treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients with checkpoint inhibitor-refractory advanced cutaneous melanoma was presented today at the 2021 European Society for M |
TIL Price Returns
| 1-mo | -21.57% |
| 3-mo | -44.44% |
| 6-mo | -72.48% |
| 1-year | -66.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -64.93% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...